Indiana-based RxLightning, a creator of a comprehensive platform for streamlining specialty medication access and affordability, has raised $17.5 million in Series A funding to bolster its platform for streamlining specialty medication access. The funding round, led by LRVHealth and featuring participation from McKesson Ventures, Novartis, Onco360, Hearst Ventures, and HealthX Ventures, brings the total amount raised to $20.5 million. RxLightning's comprehensive solution digitizes and automates the historically manual onboarding process for specialty medications, enabling healthcare providers to streamline patient enrollment, reduce paperwork, and expedite speed-to-therapy. Through its MedAccess Ecosystem, the platform facilitates seamless communication and collaboration among patients, providers, specialty pharmacies, and pharmaceutical manufacturers. Additionally, RxLightning's modular platform automates key processes such as the Food and Drug Administration's Risk Evaluation and Mitigation Strategies program, patient eligibility and coverage verification, and enrollment in financial assistance programs. By eliminating access barriers, RxLightning aims to improve patient outcomes and enhance medication access in the specialty medication landscape.
With the newly secured funding, RxLightning plans to support its growth trajectory and further expand its presence in the healthcare industry. The company has already digitized forms for over one thousand two hundred specialty drugs, incorporating custom logic and smart-pick menus, and continuously updates its platform to accommodate new medications entering the market. This infusion of capital will fuel RxLightning's mission to transform the specialty medication landscape by improving efficiency, communication, and accessibility for patients and healthcare providers alike.